Bartomeu Massuti

9PUBLICATIONS
156CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersPacific Peoples life course
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 28, 2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

|Mar 10, 2026
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

Belén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre

|Jan 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|Jan 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Glenwood D Goss, Gail E Darling, Virginie Westeel

|Jun 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim

|Apr 17, 2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.

Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti

Pageof 2

Frequent Collaborators

5 joint publications

Javier De Castro Carpeño

5 joint publications

Ernest Nadal

4 joint publications

Manuel Dómine

4 joint publications

Mariano Provencio Pulla